论文部分内容阅读
作者比较了Ondansetron与安慰剂抗顺铂引起的恶心和呕吐的疗效及安全性。 28例癌症病人接受顺铂50～120mg/m~2,采用随机双盲安慰剂的对比方法,接受Ondansetron或安慰剂(生理盐水)治疗。在顺铂治疗前30分钟、治疗后4小时和8小时,分别给予Ondansetron(本品0.15mg/kg溶于50 ml生理盐水中),于15分钟内静脉滴入。结果发现Ondansetron治疗组的恶心、呕吐显著减少。首次发现恶心、呕吐中值时
The authors compared the efficacy and safety of Ondansetron and placebo against cisplatin-induced nausea and vomiting. Twenty-eight cancer patients received cisplatin 50 to 120 mg / m 2 and were treated with Ondansetron or placebo (normal saline) in a randomized, double-blind, placebo-controlled manner. Ondansetron (0.15 mg / kg in 50 ml of normal saline) was given 30 minutes before cisplatin treatment, 4 hours after treatment and 8 hours after treatment and intravenously in 15 minutes. Nandansetron treatment group was found to be significantly reduced nausea and vomiting. The first time to find nausea, vomiting median